新西兰的新法案承认外国批准,扩大了供应商规定权利的范围,允许紧急替代药物,从而加快了药物的获取速度。 New Zealand's new bill speeds drug access by recognizing foreign approvals, expands provider prescribing rights, and allows emergency alternative medicines.

新西兰2025年10月21日提出的《药品修正法案》旨在加速获得新药品,允许另外两个国家批准的药品未经单独的医疗安全许可使用。 New Zealand's Medicines Amendment Bill, introduced October 21, 2025, aims to speed up access to new medicines by allowing drugs approved in two other countries to be used without separate Medsafe approval. 它扩大了药剂师和护士执业者的权利,特别是在农村地区,并允许紧急使用替代资助药物。 It expands prescribing rights for pharmacists and nurse practitioners, especially in rural areas, and permits emergency use of alternative funded medicines. 计划进行的一项修正将允许在国内医疗会议上销售未经批准的药物,这有可能在十年内节省9 000万美元。 A planned amendment would allow marketing of unapproved drugs at domestic medical conferences, potentially saving $90 million over ten years. 该法案经卫生委员会审查后修订,允许通过条例确定符合资格的国家,从而增加灵活性。 The bill, revised after Health Committee review, allows qualifying countries to be set by regulation, increasing flexibility. 虽然得到广泛支持,但对于时间安排和缺乏关于销售修正的公众协商,仍然存在关切。 While supported broadly, concerns remain over timing and lack of public consultation on the marketing amendment.